share_log

上海医药(601607.SH):硝酸异山梨酯注射液通过仿制药一致性评价

SH PHARMA (601607.SH): Isosorbide dinitrate injection has passed the consistency evaluation of generic drugs.

Gelonghui Finance ·  Jan 2 16:50

On January 2, Gelonghui reported that SH PHARMA (601607.SH) announced that its wholly-owned subsidiary, Shanghai SH PHARMA First Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as 'SH PHARMA First Biochemical'), received the 'Pharmaceutical Supplement Application Approval Notice' (Notice No: 2024B05558) issued by the National Medical Products Administration regarding Isosorbide Dinitrate Injection (hereinafter referred to as 'the Pharmaceutical'), which has passed the consistency evaluation of quality and efficacy for generic drugs.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment